Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has shared an announcement.
Shanghai Fosun Pharmaceutical reported its audited financial results for the year ending December 31, 2024, highlighting a slight decrease in revenue to RMB 40,910 million from RMB 41,249 million in 2023. Despite this, the company achieved a significant increase in operating profit, rising to RMB 2,780 million from RMB 1,100 million the previous year, and improved its net profit margin to 8.59%. These results reflect the company’s enhanced operational efficiency and strategic focus on profitability, which may positively impact its market positioning and stakeholder confidence.
More about Shanghai Fosun Pharmaceutical (Group) Co
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company based in China, primarily engaged in the pharmaceutical industry. The company focuses on the development, manufacturing, and sale of pharmaceutical products, medical devices, and healthcare services.
YTD Price Performance: 7.95%
Average Trading Volume: 5,063
Technical Sentiment Signal: Hold
Current Market Cap: $8.24B
See more data about 2196 stock on TipRanks’ Stock Analysis page.